Webinar: Influencing with Retina UK
The latest webinar from Retina UK.
Search results
The latest webinar from Retina UK.
The latest research news from Retina UK.
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
SparingVision have announced this week that they have dosed all participants in their phase 1/2 PRODYGY clinical trial for SPVN06, a gene agnostic therapy aimed at slowing disease progression in Retinitis Pigmentosa (RP).
Ocugen have recently announced that they have completed enrolment and dosing in their pivotal phase 2/3 trial of OCU410ST ahead of schedule.
VeonGen has reported encouraging early results from a clinical trial of VG801, an investigational gene therapy for Startgardt disease, a genetic retinal condition that currently has no approved treatments.
A groundbreaking technology that uses light to control nerve cells has been recognised with the 2026 Nobel Prize.
Researchers at the University of Wisconsin-Madison have identified a potential way to make CRISPR gene editing more efficient in retinal cells, which could eventually help to develop treatments for inherited retinal dystrophies (IRDs).
For Jane and Cindy, books have always been more than entertainment. They are a source of comfort, escape and connection – and now, through our new ‘Talking’ Books Peer Support Group, they are a way to bring people together and feel less alone.
Skydiving is an exhilarating experience, and you can do this while supporting our cause. Various dates and locations are available across the UK.